Caplin Point Laboratories · NSE: CAPLIPOINT · BSE: 524742
Q4 FY20 results · Jan–Mar 2020
Caplin Point Laboratories reported revenue from operations of ₹100.12 crore (down 28.9% from Q4 FY19) and net profit of ₹50.15 crore (up 24.4% from Q4 FY19) for Q4 FY20 (Jan–Mar 2020), on a standalone basis.
| Item | Q4 FY20 | Q4 FY19 | YoY | Q3 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 100.12 | 140.74 | −28.9% | 154.17 | −35.1% |
| Other income | 33.01 | 3.31 | +896.0% | 8.43 | +291.5% |
| Total income | 133.14 | 144.06 | −7.6% | 162.61 | −18.1% |
| Profit before tax | 65.81 | 55.33 | +18.9% | 60.59 | +8.6% |
| Net profit for the period | 50.15 | 40.32 | +24.4% | 47.59 | +5.4% |
| EPS, basic (₹) | 6.63 | 5.34 | +24.2% | 6.29 | +5.4% |
| Net margin (%) | 50.1 | 28.7 | 30.9 |
Standalone
- Filed with BSE
- 22 Jun 2020, 15:34 IST
- Board meeting
- 18 Jun 2020
- Period
- 01 Jan 2020 to 31 Mar 2020
- Review status
- Audited
- Source
- XBRL filing on BSE